5 months ago
PVLA
AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Industries:
Analyst Ranking
Top 13%
#639 out of 5244 analysts
Average Return
+71.46%
Win Rate
85%17 out of 20
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inozyme Pharma IncINZY | +270.37% | $1.08 | $4.00 | 2025-03-12 - 2025-07-01 | Buy |
Palvella Therapeutics IncPVLA | +215.25% | $39.07 | $123.17 | 2025-08-06 - 2026-04-08 | Buy |
Liquidia CorpLQDA | +183.15% | $9.79 | $27.72 | 2024-08-19 - 2025-08-18 | Strong Buy |
Liquidia CorpLQDA | +150.26% | $15.26 | $38.19 | 2025-05-09 - 2026-04-08 | Strong Buy |
Apellis Pharmaceuticals IncAPLS | +135.20% | $17.30 | $40.69 | 2025-05-09 - 2026-04-08 | Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | 2 | Strong Buy | $143.00 | +16.10% | Upgrades | 5 months ago |
Liquidia CorpLQDA | 4 | Strong Buy | $41.00 | +7.36% | Maintains | 8 months ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $27.00 | +106.58% | Maintains | 8 months ago |
Ardelyx IncARDX | 2 | Buy | $12.00 | +96.72% | Maintains | 8 months ago |
Apellis Pharmaceuticals IncAPLS | 2 | Buy | $50.00 | +22.88% | Maintains | 8 months ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $122.00 | +262.34% | Maintains | 9 months ago |
Tvardi Therapeutics IncTVRD | 1 | Buy | $62.00 | +1,932.79% | Initiates Coverage On | 9 months ago |
Inozyme Pharma IncINZY | 2 | Hold | $4.00 | 0.00% | Downgrades | a year ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | N/A | Maintains | a year ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.